289 related articles for article (PubMed ID: 20939815)
1. False positives in the early stages of drug discovery.
Sink R; Gobec S; Pečar S; Zega A
Curr Med Chem; 2010; 17(34):4231-55. PubMed ID: 20939815
[TBL] [Abstract][Full Text] [Related]
2. Frequent hitters: nuisance artifacts in high-throughput screening.
Yang ZY; He JH; Lu AP; Hou TJ; Cao DS
Drug Discov Today; 2020 Apr; 25(4):657-667. PubMed ID: 31987936
[TBL] [Abstract][Full Text] [Related]
3. Integration of virtual and high throughput screening in lead discovery settings.
Polgár T; Keseru GM
Comb Chem High Throughput Screen; 2011 Dec; 14(10):889-97. PubMed ID: 21843143
[TBL] [Abstract][Full Text] [Related]
4. Modern drug discovery technologies: opportunities and challenges in lead discovery.
Guido RV; Oliva G; Andricopulo AD
Comb Chem High Throughput Screen; 2011 Dec; 14(10):830-9. PubMed ID: 21843147
[TBL] [Abstract][Full Text] [Related]
5. Non-stoichiometric inhibition in integrated lead finding - a literature review.
Klumpp M
Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
[TBL] [Abstract][Full Text] [Related]
6. Scopy: an integrated negative design python library for desirable HTS/VS database design.
Yang ZY; Yang ZJ; Lu AP; Hou TJ; Cao DS
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32892221
[TBL] [Abstract][Full Text] [Related]
7. Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.
Shun TY; Lazo JS; Sharlow ER; Johnston PA
J Biomol Screen; 2011 Jan; 16(1):1-14. PubMed ID: 21160066
[TBL] [Abstract][Full Text] [Related]
8. Case studies of minimizing nonspecific inhibitors in HTS campaigns that use assay-ready plates.
Liu Y; Beresini MH; Johnson A; Mintzer R; Shah K; Clark K; Schmidt S; Lewis C; Liimatta M; Elliott LO; Gustafson A; Heise CE
J Biomol Screen; 2012 Feb; 17(2):225-36. PubMed ID: 21940710
[TBL] [Abstract][Full Text] [Related]
9. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
10. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series.
Duffy BC; Zhu L; Decornez H; Kitchen DB
Bioorg Med Chem; 2012 Sep; 20(18):5324-42. PubMed ID: 22938785
[TBL] [Abstract][Full Text] [Related]
11. Lead discovery for mammalian elongation of long chain fatty acids family 6 using a combination of high-throughput fluorescent-based assay and RapidFire mass spectrometry assay.
Takamiya M; Sakurai M; Teranishi F; Ikeda T; Kamiyama T; Asai A
Biochem Biophys Res Commun; 2016 Nov; 480(4):721-726. PubMed ID: 27793673
[TBL] [Abstract][Full Text] [Related]
12. Industrial medicinal chemistry insights: neuroscience hit generation at Janssen.
Tresadern G; Rombouts FJR; Oehlrich D; Macdonald G; Trabanco AA
Drug Discov Today; 2017 Oct; 22(10):1478-1488. PubMed ID: 28669605
[TBL] [Abstract][Full Text] [Related]
13. Biophysics: for HTS hit validation, chemical lead optimization, and beyond.
Genick CC; Wright SK
Expert Opin Drug Discov; 2017 Sep; 12(9):897-907. PubMed ID: 28658992
[TBL] [Abstract][Full Text] [Related]
14. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens.
Huth JR; Mendoza R; Olejniczak ET; Johnson RW; Cothron DA; Liu Y; Lerner CG; Chen J; Hajduk PJ
J Am Chem Soc; 2005 Jan; 127(1):217-24. PubMed ID: 15631471
[TBL] [Abstract][Full Text] [Related]
15. Toxicology Strategies for Drug Discovery: Present and Future.
Blomme EA; Will Y
Chem Res Toxicol; 2016 Apr; 29(4):473-504. PubMed ID: 26588328
[TBL] [Abstract][Full Text] [Related]
16. The essential roles of chemistry in high-throughput screening triage.
Dahlin JL; Walters MA
Future Med Chem; 2014 Jul; 6(11):1265-90. PubMed ID: 25163000
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening in drug design and development.
Sousa SF; Cerqueira NM; Fernandes PA; Ramos MJ
Comb Chem High Throughput Screen; 2010 Jun; 13(5):442-53. PubMed ID: 20236061
[TBL] [Abstract][Full Text] [Related]
18. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
[TBL] [Abstract][Full Text] [Related]
19. Biodiversity of small molecules--a new perspective in screening set selection.
Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
[TBL] [Abstract][Full Text] [Related]
20. Polymerase assays for lead discovery: An overall review of methodologies and approaches.
Nasiri AH; Nasiri HR
Anal Biochem; 2018 Dec; 563():40-50. PubMed ID: 30291837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
